

個人履歷表

邱昌芳 教授 Professor Chiu, Chang-Fang

主要學歷			
學校名稱	學位	起迄年月	科技專長
美國紐約康奈爾大學	哲學博士	1987/9~1991/5	癌細胞生物學
美國紐約史隆凱特靈癌病中心	Research Fellow	1987/2~1987/8	腫瘤醫學
美國耶魯大學	進修	1986/7~1987/1	抗癌藥理
台北醫學院	醫學士	1973/8~1980/6	醫學
經歷（依服務時間先後順序）			
服務機構及單位		職稱	起迄年月
現任：中國醫藥大學醫學院醫學系		教授	2008/02~迄今
中國醫藥大學附設醫院癌症中心		副院長	2010/01~迄今
行政院衛生福利部癌症防治政策委員會		諮議委員	2009/01~迄今
行政院衛生福利部食品藥物管理署藥物審議委員		委員	2015/01~ 迄今
財團法人醫藥品查驗中心（CDE）		顧問兼審查員 （臨床組）	2009/07~迄今
國家衛生研究院 TCOG 安全監督委員會		委員	2008/07~迄今
衛生福利部中央健保署藥物給付項目及支付標準共同擬訂會議（藥品）		委員	2015/01~迄今
衛生福利部中央健保署藥事小組		委員	2013/01~迄今

最近三年已發表之學術性著作清單

Publications (2012~):

1. Ip SW, Lan SH, Huang AC, Yang JS, Chen YY, Huang HY, Lin ZP, Hsu YM, Yang MD, **Chiu CF**, Chung JG. Capsaicin induces apoptosis in SCC-4 human tongue cancer cells through mitochondria-dependent and -independent pathways. Environ Toxicol. 2012 May;27(6):332-41.
2. Wu HC, Chang CH, Tsai RY, Lin CH, Wang RF, Tsai CW, Chen KB, Yao CH, **Chiu CF**, Bau DT, Lin CC. Significant association of methylenetetrahydrofolate reductase single nucleotide polymorphisms with prostate cancer susceptibility in Taiwan. Anticancer Res. 2010 Sep;30(9):3573-7.
3. Bai LY, Omar HA, **Chiu CF**, Chi ZP, Hu JL, Weng JR. Antitumor effects of (S)-HDAC42, a phenylbutyrate-derived histone deacetylase inhibitor, in multiple myeloma cells. Cancer Chemother Pharmacol. 2011 Aug;68(2):489-96.

4. Chang NW, Tsai MH, Lin C, Hsu HT, Chu PY, Yeh CM, **Chiu CF**, Yeh KT. Fenofibrate exhibits a high potential to suppress the formation of squamous cell carcinoma in an oral-specific 4-nitroquinoline 1-oxide/arecoline mouse model. *Biochim Biophys Acta*. 2011 Apr;1812(4):558-64.
5. Bau DT, Chang CH, Tsai MH, **Chiu CF**, Tsou YA, Wang RF, Tsai CW, Tsai RY. Association between DNA repair gene ATM polymorphisms and oral cancer susceptibility. *Laryngoscope*. 2010 Dec;120(12):2417-22.
6. Viprakasit V, Ibrahim H, Ha SY, Ho PJ, Li CK, Chan LL, **Chiu CF**, Sutcharitchan P, Habr D, Domokos G, Roubert B, Xue HL, Bowden DK, Lin KH. Clinical efficacy and safety evaluation of tailoring iron chelation practice in thalassaemia patients from Asia-Pacific: a subanalysis of the EPIC study of deferasirox. *Int J Hematol*. 2011 Mar;93(3):319-28.
7. Guidelines for the use of antifungal agents in patients with invasive fungal infections in Taiwan--revised 2009. *J Microbiol Immunol Infect*. 2010 Jun;43(3):258-63.
8. Bai LY, Ma Y, Kulp SK, Wang SH, **Chiu CF**, Frissora F, Mani R, Mo X, Jarjoura D, Byrd JC, Chen CS, Muthusamy N. OSU-DY7, a novel D-tyrosinol derivative, mediates cytotoxicity in chronic lymphocytic leukaemia and Burkitt lymphoma through p38 mitogen-activated protein kinase pathway. *Br J Haematol*. 2011 Jun;153(5):623-33.
9. Bai LY, **Chiu CF**, Pan SL, Sargeant AM, Shieh TM, Wang YC, Weng JR. Antitumor activity of a novel histone deacetylase inhibitor (S)-HDAC42 in oral squamous cell carcinoma. *Oral Oncology*. 2011 Dec;47(12):1127-33.
10. Tsou YA, Tsai CW, Tsai MH, Chang WS, Li FJ, Liu YF, **Chiu CF**, Lin CC, Bau DT. Association of caveolin-1 genotypes with nasopharyngeal carcinoma susceptibility in Taiwan. *Anticancer Res*. 2011 Oct;31(10):3629-32.
11. Wang CH, Wu KH, Yang YL, Peng CT, Tsai FJ, Lin DT, **Chiu CF**, Lin CC, Bau DT. Association between Ataxia Telangiectasia Mutated Gene Polymorphisms and Childhood Leukemia in Taiwan. *Chinese Journal of Physiology*. 2011 Dec 31;54(6):413-8.
12. Yeh SP, Lo WJ, Lin CL, Liao YM, Lin CY, Bai LY, Liang JA, **Chiu CF***. Ann Hematol. Anti-leukemic therapies induce cytogenetic changes of human bone marrow-derived mesenchymal stem cells. *Annals of Hematology*. 2012 Feb;91(2):163-72.
13. Yu FS, Huang AC, Yang JS, Yu CS, Lu CC, Chiang JH, **Chiu CF**, Chung JG. Environ Toxicol. Safrole induces cell death in human tongue squamous cancer SCC-4 cells through mitochondria-dependent caspase activation cascade apoptotic signaling pathways. *Environ Toxicol*. 2012 Jul;27(7):433-44.
14. Bai LY, Weng JR, Lo WJ, Yeh SP, Wu CY, Wang CY, **Chiu CF**, Lin CW. Inhibition of hedgehog signaling induces monocytic differentiation of HL-60 cells. *Leuk Lymphoma*. 2012 Jun;53(6):1196-202.
15. Weng JR, Bai LY, **Chiu CF**, Wang YC, Tsai MH. The dietary phytochemical 3,3'-diindolylmethane induces G2/M arrest and apoptosis in oral squamous cell carcinoma by modulating Akt-NF- κ B, MAPK, and p53 signaling. *Chem Biol Interact*. 2012 Feb 5;195(3):224-30.
16. Yeh SP, Liao YM, Lo WJ, Lin CL, Bai LY, Lin CY, Hsieh CY, Chang YC, Huang YT, **Chiu CF**. Kinetics of T helper subsets and associated cytokines correlate well with the clinical activity of graft-versus-host disease. *PLoS One*. 2012;7(9):e44416.
17. Huang AC, Chang CL, Yu CS, Chen PY, Yang JS, Ji BC, Lin TP, **Chiu CF**, Yeh SP, Huang YP, Lien JC, Chung JG. Induction of apoptosis by curcumin in murine myelomonocytic leukemia WEHI-3 cells is mediated via endoplasmic reticulum stress and mitochondria-dependent pathways. *Environ Toxicol*. 2013 May;28(5):255-66.
18. Lin CC, Chang HW, Lin CY, **Chiu CF***, Yeh SP. The clinical features and prognosis of phyllodes tumors: a single institution experience in Taiwan. *Int J Clin Oncol*. 2013 Aug;18(4):614-20.
19. Lin PH, Lin CC, Yang HI, Li LY, Bai LY, **Chiu CF**, Liao YM, Lin CY, Hsieh CY, Lin CY, Ho CM, Yang SF, Peng CT, Tsai FJ, Yeh SP. Prognostic impact of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with internal tandem duplication of FLT3. *Leuk Res*. 2013

Mar;37(3):287-92.

20. Lee KD, Chen HH, Wang HM, Tsao CJ, Hsu TC, **Chiu CF**, Su WC, Wang JY. An open-label safety study of first-line bevacizumab in combination with standard chemotherapy in Chinese patients with metastatic colorectal cancer treated in an expanded access program in Taiwan. *Oncology*. 2013;84(5):299-304.
21. Wang CH, Lai YL, Chang WS, Wu KH, Lane HY, **Chiu CF**, Tsai FJ, Lin CC, Bau DT. Significant association of caveolin-1 single nucleotide polymorphisms with childhood leukemia in Taiwan. *Cancer Genomics Proteomics*. 2013 Mar-Apr;10(2):75-9.
22. Weng JR, Bai LY, **Chiu CF**, Hu JL, Chiu SJ, Wu CY. Cucurbitane Triterpenoid from *Momordica charantia* Induces Apoptosis and Autophagy in Breast Cancer Cells, in Part, through Peroxisome Proliferator-Activated Receptor γ Activation. *Evid Based Complement Alternat Med*. 2013;2013:935675.
23. Lin PH, Yeh MH, Liu LC, Chen CJ, Tsui YC, Su CH, Wang HC, Liang JA, Chang HW, Wu HS, Yeh SP, Li LY, **Chiu CF***. Clinical and pathologic risk factors of tumor recurrence in patients with node-negative early breast cancer after mastectomy. *J Surg Oncol*. 2013 Nov;108(6):352-7.
24. Bai LY, Weng JR, **Chiu CF**, Wu CY, Yeh SP, Sargeant AM, Lin PH, Liao YM. OSU-A9, an indole-3-carbinol derivative, induces cytotoxicity in acute myeloid leukemia through reactive oxygen species-mediated apoptosis. *Biochem Pharmacol*. 2013 Nov 15;86(10):1430-40.
25. Lin CC, Chen TT, Lin CY, Hsieh CY, Lin PH, Chien CR, **Chiu CF**, Yeh SP. Prognostic analysis of adjuvant chemotherapy in patients with nasopharyngeal carcinoma. *Future Oncol*. 2013 Oct;9(10):1469-76.
26. Bai LY, Weng JR, Hu JL, Wang D, Sargeant AM, **Chiu CF**. G15, a GPR30 antagonist, induces apoptosis and autophagy in human oral squamous carcinoma cells. *Chem Biol Interact*. 2013 Nov 25;206(2):375-84.
27. Hsu C, Tsou HH, Lin SJ, Wang MC, Yao M, Hwang WL, Kao WY, **Chiu CF**, Lin SF, Lin J, Chang CS, Tien HF, Liu TW, Chen PJ, Cheng AL. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study. *Hepatology*. 2014 Jun;59(6):2092-100.
28. **Chiu CF**, Bai LY, Kapuriya N, Peng SY, Wu CY, Sargeant AM, Chen MY, Weng JR. Antitumor effects of BI-D1870 on human oral squamous cell carcinoma. *Cancer Chemother Pharmacol*. 2014 Feb;73(2):237-47.
29. Yeh SP, Lo WC, Hsieh CY, Bai LY, Lin CC, Lin PH, Lin CY, Liao YM, **Chiu CF**. Palonosetron and dexamethasone for the prevention of nausea and vomiting in patients receiving allogeneic hematopoietic stem cell transplantation. *Support Care Cancer*. 2014 May;22(5):1199-206.
30. Tang ST, Liu TW, Chow JM, **Chiu CF**, Hsieh RK, Chen CH, Liu LN, Feng WL. Associations between accurate prognostic understanding and end-of-life care preferences and its correlates among Taiwanese terminally ill cancer patients surveyed in 2011-2012. *Psychooncology*. 2014 Jan 28.
31. Lin WY, Chiu TY, Ho CT, Davidson LE, Hsu HS, Liu CS, **Chiu CF**, Peng CT, Chen CY, Hu WY, Hsu LN, Li CI, Li TC, Lin CY, Chen CY, Lin CC. Hospice shared-care saved medical expenditure and reduced the likelihood of intensive medical utilization among advanced cancer patients in Taiwan-a nationwide survey. *Support Care Cancer*. 2014 Jul;22(7):1907-14.
32. Ko BS, Chang CS, Chang MC, Chen TY, Chiou TJ, **Chiu CF**, Huang WL, Kao WY, Lan YJ, Lin SF, Tan TD, Tang JL, Tzeng CH, Wang PN, Yet SP, Tien HF. Guidelines for treating iron overload in myelodysplastic syndromes: a Taiwan consensus statement. *Int J Hematol*. 2014 Jun 13.
33. Liu CY, Chen WT, Kung PT, **Chiu CF**, Wang YH, Shieh SH, Tsai WC. Characteristics, survival, and related factors of newly diagnosed colorectal cancer patients refusing cancer treatments under a universal health insurance program. *BMC Cancer*. 2014 Jun 17;14:446.
34. Tsai HJ, Lin SF, Chen CC, Chen TY, Su WC, Hwang WL, Lin JC, Chiou TJ, Kao WY, **Chiu CF**, Chang YF, Chang JS, Chang MC, Su IJ. Long term results of a phase II trial with front-line concurrent

- chemoradiotherapy followed by consolidation chemotherapy for localized nasal natural killer/T-cell lymphoma. *Eur J Haematol.* 2014 Jun 24.
35. Tang ST, Liu TW, Liu LN, **Chiu CF**, Hsieh RK, Tsai CM. Physician-patient end-of-life care discussions: Correlates and associations with end-of-life care preferences of cancer patients-a cross-sectional survey study. *Palliat Med.* 2014, 28:1222-1230
 36. Huang HL, Kung PT, **Chiu CF**, Wang YH, Tsai WC. Factors associated with lung cancer patients refusing treatment and their survival: a national cohort study under a universal health insurance in Taiwan. *PLoS One.* 2014 Jul 7;9(7):e101731.
 37. Lien MY, Liu LC, Wang HC, Yeh MH, Chen CJ, Yeh SP, [Bai LY](#), [Liao YM](#), [Lin CY](#), [Hsieh CY](#), Lin CC, Li LY, Lin PH and **Chiu CF**. Safety and Efficacy of Pegylated Liposomal Doxorubicin-based Adjuvant Chemotherapy in Patients with Stage I-III Triple-negative Breast Cancer. *Anticancer Research*, 2014.
 38. Li-Yuan Baia, Wei-Yu Linb, **Chang-Fang Chiu** and Jing-Ru Wengc,* Anti-tumor Activities of Triterpenes from *Syzygium kusukusense*. *Natural Product Communications* 2014, 9(11):1557-1558
 39. J. S. Chen¹, C. Hsu, N.J. Chiang, C. S. Tsai, H. H. Tsou, S. F. Huang, L. Y. Bai, I. C. Chang, H. S. Shiah, C. L. Ho, C. J. Yen, K. D. Lee, **C. F. Chiu**, K. M. Rau, M. S. Yu, Y. Yang, R. K. Hsieh, J. Y. Chang, Y. S. Shan,, Y. Chao, L. T. Chen, on behalf of the Taiwan Cooperative Oncology Group. A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer. *Ann Oncol* 2015, 26:943-949
 40. S-P Yeh, C-C Lin, C-H Lin, W-C Lo, T-T Chen, W-J Lo, C-L Lin and **C-F Chiu**. Second haploidentical peripheral blood stem cell transplantation for treatment of acute leukemia with relapse after first allogeneic peripheral blood stem cell transplantation. *Bone Marrow Transplantation* 2015, 1-3. doi:10.1038/bmt.2015.67